Clinical application of autophagy proteins as prognostic biomarkers in colorectal cancer: a meta-analysis

Future Oncol. 2022 Oct;18(31):3537-3549. doi: 10.2217/fon-2022-0458. Epub 2022 Oct 3.

Abstract

Aim: To evaluate the prognostic value of autophagy proteins in colorectal cancer (CRC). Methods: Six potential autophagy proteins were analyzed (Beclin-1, LC3A, LC3B, ULK1, ATG10 and p62). Hazard ratios (HRs) and 95% CIs for overall survival (OS) of CRC patients were calculated. Results: A total of 20 studies were included. High expression of LC3B and p62 was associated with favorable OS (HR: 0.56, 95% CI: 0.40-0.80; HR: 0.76, 95% CI: 0.61-0.96), whereas high expression of Beclin-1 (HR: 1.47, 95% CI: 1.05-2.06) and ULK1 (HR: 1.92. 95% CI: 1.05-3.53) might predict worse OS in CRC patients. Conclusion: Beclin-1, LC3B and p62 might act as promising prognostic biomarkers for CRC. High LC3 and p62 expression can be reliable tools for metastasis prediction.

Keywords: Beclin-1; LC3; autophagy; colorectal cancer; meta-analysis; p62.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Apoptosis Regulatory Proteins* / metabolism
  • Autophagy
  • Beclin-1 / genetics
  • Beclin-1 / metabolism
  • Biomarkers
  • Biomarkers, Tumor / metabolism
  • Colorectal Neoplasms* / pathology
  • Humans
  • Microtubule-Associated Proteins / genetics
  • Microtubule-Associated Proteins / metabolism
  • Prognosis

Substances

  • Beclin-1
  • Apoptosis Regulatory Proteins
  • Microtubule-Associated Proteins
  • Biomarkers
  • Biomarkers, Tumor